ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 219,14
0,38%
Dow Jones
39 512,84
0,32%
DAX
18 772,85
0,50%
Brent Oil
82,33
-0,07%
Bitcoin
60 899,97
-0,89%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Immutep Ltd (IMMP)

  7. Immutep Ltd (IMMP) Actualités

IMMP

Immutep (IMMP)

Immutep Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:IMMP
DateHeureSourceTitreSymboleSociété
02/05/202414h00GlobeNewswire Inc.Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue SarcomaNASDAQ:IMMPImmutep Ltd
29/04/202414h00GlobeNewswire Inc.Immutep Quarterly Activities Report Q3 FY24NASDAQ:IMMPImmutep Ltd
24/04/202414h00GlobeNewswire Inc.Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort BNASDAQ:IMMPImmutep Ltd
18/04/202414h00GlobeNewswire Inc.Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761NASDAQ:IMMPImmutep Ltd
17/04/202414h00GlobeNewswire Inc.Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung CancerNASDAQ:IMMPImmutep Ltd
05/03/202414h00GlobeNewswire Inc.Immutep Announces First Clinical Data from 90mg Dosing of EftiNASDAQ:IMMPImmutep Ltd
30/01/202422h01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMMPImmutep Ltd
30/01/202414h00GlobeNewswire Inc.Immutep Quarterly Activities Report Q2 FY24NASDAQ:IMMPImmutep Ltd
04/01/202414h00GlobeNewswire Inc.First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial CancerNASDAQ:IMMPImmutep Ltd
21/12/202314h00GlobeNewswire Inc.Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung CancerNASDAQ:IMMPImmutep Ltd
07/12/202314h00GlobeNewswire Inc.Immutep Receives A$2.6 million R&D Tax Incentive from French GovernmentNASDAQ:IMMPImmutep Ltd
22/11/202314h00GlobeNewswire Inc.Immutep Announces Site Expansion for INSIGHT-003 Phase I TrialNASDAQ:IMMPImmutep Ltd
09/11/202314h00GlobeNewswire Inc.Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell CarcinomaNASDAQ:IMMPImmutep Ltd
06/11/202314h00GlobeNewswire Inc.Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast CancerNASDAQ:IMMPImmutep Ltd
03/11/202317h00GlobeNewswire Inc.Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung CancerNASDAQ:IMMPImmutep Ltd
02/11/202313h00GlobeNewswire Inc.Immutep to Participate in November Investor EventsNASDAQ:IMMPImmutep Ltd
31/10/202313h00GlobeNewswire Inc.Immutep Quarterly Activities Report Q1 FY24NASDAQ:IMMPImmutep Ltd
25/10/202314h00GlobeNewswire Inc.Immutep receives ~A$1.13 million R&D Tax IncentiveNASDAQ:IMMPImmutep Ltd
24/10/202314h00GlobeNewswire Inc.Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023NASDAQ:IMMPImmutep Ltd
23/10/202314h00GlobeNewswire Inc.Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung CancerNASDAQ:IMMPImmutep Ltd
16/10/202314h00GlobeNewswire Inc.Immutep Announces Publication of Abstracts at ESMO Congress 2023NASDAQ:IMMPImmutep Ltd
03/10/202314h00GlobeNewswire Inc.Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual MeetingNASDAQ:IMMPImmutep Ltd
21/09/202314h00GlobeNewswire Inc.Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial UseNASDAQ:IMMPImmutep Ltd
05/09/202315h00GlobeNewswire Inc.Immutep to Participate in September Investor ConferencesNASDAQ:IMMPImmutep Ltd
01/08/202314h00GlobeNewswire Inc.Immutep Receives Positive Scientific Advice from European Medicines AgencyNASDAQ:IMMPImmutep Ltd
31/07/202314h00GlobeNewswire Inc.Immutep Quarterly Activities Report Q4 FY23NASDAQ:IMMPImmutep Ltd
31/07/202314h00GlobeNewswire Inc.Immutep to Present Overall Survival Data in 1st Line Non-Small Cell Lung Cancer Accepted for Oral Presentation at ESMO Congress 2023NASDAQ:IMMPImmutep Ltd
28/07/202314h00GlobeNewswire Inc.First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue SarcomaNASDAQ:IMMPImmutep Ltd
28/06/202312h02Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:IMMPImmutep Ltd
27/06/202314h00GlobeNewswire Inc.Immutep Completes A$80 Million Capital RaiseNASDAQ:IMMPImmutep Ltd
 Showing the most relevant articles for your search:NASDAQ:IMMP

Dernières Valeurs Consultées

EU
AI
Air Liquide
EU
RI
Pernod Ricard
EU
ACA
Credit Agricole
EU
VK
Vallourec
EU
EN
Bouygues
NYSE
DIS
Walt Disney
NYSE
NKE
Nike
NYSE
MRK
Merck
SPI
SP500
S&P 500
EU
CS
Axa
NASDAQ
AAPL
Apple
EU
AF
Air FranceKLM
NASDAQ
AMZN
Amazon.com
NASDAQ
NVDA
NVIDIA
EU
DG
Vinci
NYSE
JPM
JP Morgan Chase
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés